CD4+_NP CD25+_NP T-Cell_NN Production_NN in_IN Healthy_JJ Humans_NNS and_CC in_IN Patients_NNS with_IN Thymic_NP Hypoplasia_NP Regulatory_NP T_NN cells_NNS are_VBP found_VBN primarily_RB in_IN the_DT CD4+_NP CD25+_NP fraction_NN of_IN T_NN cells_NNS and_CC play_VB an_DT important_JJ role_NN in_IN the_DT prevention_NN of_IN autoimmunity_NN ._SENT We_PP examined_VBD CD4+_NP CD25+_NP T_NN cells_NNS in_IN 33_CD healthy_JJ children_NNS and_CC adults_NNS and_CC compared_VBN them_PP to_TO a_DT population_NN with_IN an_DT inherited_VBN form_NN of_IN thymic_JJ hypoplasia_NN and_CC a_DT predisposition_NN to_TO autoimmune_JJ disease_NN ._SENT Absolute_JJ numbers_NNS of_IN CD4+_NP CD25+_NP T_NN cells_NNS were_VBD markedly_RB higher_JJR in_IN healthy_JJ infants_NNS than_IN in_IN infants_NNS with_IN chromosome_NN 22q11.2_JJ deletion_NN syndrome_NN ._SENT Regulatory_JJ T_NN cells_NNS constitute_VBP an_DT important_JJ contributor_NN to_TO the_DT state_NN of_IN tolerance_NN ._SENT Little_RB is_VBZ known_VBN about_IN their_PP$ function_NN and_CC production_NN in_IN humans_NNS ,_, and_CC nothing_NN is_VBZ known_VBN about_IN their_PP$ development_NN in_IN humans_NNS ._SENT Murine_JJ studies_NNS first_RB defined_VBD these_DT cells_NNS as_IN a_DT component_NN of_IN CD4+_NP CD25+_NP (_( CD4_NP CD25_NP )_) T_NN cells_NNS ._SENT Several_JJ important_JJ features_NNS of_IN these_DT murine_JJ cells_NNS have_VBP been_VBN described_VBN ._SENT They_PP exit_VBP the_DT thymus_NN from_IN day_NN 4_CD of_IN life_NN onwards_RB ,_, and_CC they_PP appear_VBP to_TO require_VB a_DT T-cell_NN receptor_NN with_IN high_JJ affinity_NN ._SENT They_PP are_VBP antigen_NN specific_JJ in_IN their_PP$ activation_NN but_CC are_VBP non-antigen_NN specific_JJ as_IN effectors_NNS ._SENT As_IN effectors_NNS ,_, they_PP are_VBP naturally_RB nonproliferative_JJ ,_, and_CC their_PP$ function_NN is_VBZ generally_RB detected_VBN by_IN their_PP$ ability_NN to_TO inhibit_VB proliferation_NN of_IN other_JJ cells_NNS or_CC other_JJ effector_NN functions_NNS ,_, such_JJ as_IN cytolytic_JJ activity_NN ._SENT Although_IN their_PP$ exact_JJ mechanism_NN of_IN action_NN is_VBZ controversial_JJ ,_, there_EX is_VBZ agreement_NN that_IN cell_NN contact_NN is_VBZ required_VBN ._SENT These_DT cells_NNS have_VBP been_VBN demonstrated_VBN to_TO be_VB responsible_JJ for_IN the_DT prevention_NN of_IN organ-specific_JJ autoimmunity_NN in_IN several_JJ murine_JJ models_NNS ._SENT Mice_NNS which_WDT have_VBP undergone_VBN a_DT thymectomy_NN between_IN days_NNS 1_CD and_CC 3_CD of_IN life_NN have_VBP a_DT delay_NN in_IN the_DT appearance_NN of_IN CD25+_NP T_NN cells_NNS ._SENT These_DT mice_NNS develop_VBP organ-specific_JJ autoimmune_JJ disease_NN ;_: the_DT specific_JJ disease_NN is_VBZ dependent_JJ on_IN the_DT strain_NN of_IN mice_NNS used_VBN ._SENT Infusion_NN of_IN CD25+_NP T_NN cells_NNS can_MD abolish_VB the_DT organ-specific_JJ autoimmune_JJ disease_NN ._SENT In_IN thymectomy_NN models_NNS ,_, the_DT ratio_NN of_IN CD25+_NP to_TO CD25-_NP T_NN cells_NNS is_VBZ normal_JJ ._SENT The_DT CD25+_NP T_NN cells_NNS appear_VBP late_RB and_CC in_IN lower_JJR numbers_NNS but_CC retain_VB their_PP$ normal_JJ proportion_NN in_IN the_DT T-cell_NN compartment_NN ._SENT This_DT has_VBZ suggested_VBN that_IN adequate_JJ quantitative_JJ production_NN of_IN regulatory_JJ T_NN cells_NNS early_JJ in_IN life_NN may_MD be_VB a_DT critical_JJ part_NN of_IN the_DT development_NN of_IN tolerance_NN ._SENT Human_JJ cells_NNS with_IN regulatory_JJ properties_NNS express_VBP very_RB high_JJ levels_NNS of_IN CD25_NP and_CC have_VB suppressive_JJ effects_NNS on_IN effector_NN functions_NNS similar_JJ to_TO that_DT seen_VBN in_IN mice_NNS ._SENT They_PP are_VBP present_JJ in_IN adults_NNS at_IN levels_NNS similar_JJ to_TO those_DT seen_VBN in_IN mice_NNS ,_, i.e._FW ,_, approximately_RB 6_CD to_TO 10_CD %_NN of_IN CD4_NP T_NN cells_NNS ._SENT The_DT studies_NNS described_VBD above_RB documented_VBN the_DT important_JJ role_NN of_IN the_DT thymus_NN in_IN the_DT production_NN of_IN CD4_NP CD25_NP T_NN cells_NNS and_CC the_DT role_NN of_IN CD4_NP CD25_NP T_NN cells_NNS in_IN the_DT prevention_NN of_IN autoimmunity_NN ._SENT In_IN this_DT study_NN ,_, we_PP examined_VBD a_DT population_NN of_IN children_NNS who_WP have_VBP thymic_JJ hypoplasia_NN as_IN a_DT result_NN of_IN a_DT heterozygous_JJ deletion_NN of_IN chromosome_NN 22q11.2_JJ ._SENT This_DT deletion_NN results_NNS in_IN a_DT phenotype_NN which_WDT has_VBZ also_RB been_VBN called_VBN DiGeorge_NP syndrome_NN ,_, velocardiofacial_JJ syndrome_NN ,_, or_CC conotruncal_JJ anomaly_NN face_NN syndrome_NN ._SENT Approximately_RB 80_CD %_NN of_IN patients_NNS with_IN the_DT deletion_NN will_MD have_VB an_DT immunodeficiency_NN as_IN a_DT consequence_NN of_IN the_DT thymic_JJ hypoplasia_NN ._SENT The_DT immunodeficiency_NN is_VBZ typically_RB a_DT pure_JJ defect_NN in_IN T-cell_NN production_NN ,_, and_CC patients_NNS have_VBP on_IN average_NN 50_CD to_TO 70_CD %_NN of_IN the_DT normal_JJ numbers_NNS of_IN T_NN cells_NNS ._SENT Autoimmune_JJ disease_NN develops_VBZ in_IN approximately_RB 10_CD %_NN of_IN patients_NNS ,_, although_IN the_DT pathophysiologic_JJ mechanism_NN for_IN this_DT is_VBZ not_RB understood_VBN ._SENT This_DT study_NN examined_VBD the_DT developmental_JJ appearance_NN of_IN CD4_NP CD25_NP T_NN cells_NNS in_IN the_DT peripheral_JJ blood_NN of_IN 33_CD children_NNS and_CC adults_NNS with_IN chromosome_NN 22q11.2_JJ deletion_NN and_CC in_IN 33_CD healthy_JJ age-matched_JJ controls_NNS in_IN an_DT effort_NN to_TO determine_VB whether_IN thymic_JJ hypoplasia_NN could_MD be_VB associated_VBN with_IN diminished_JJ numbers_NNS of_IN this_DT important_JJ T-cell_NN subset_NN ,_, as_IN is_VBZ seen_VBN in_IN mice_NNS with_IN neonatal_JJ thymectomies_NNS ._SENT Unselected_JJ patients_NNS with_IN hemizygous_JJ deletions_NNS of_IN chromosome_NN 22q11.2_JJ as_IN detected_VBN by_IN the_DT Oncor/Vysis_NP N25_NP probe_NN were_VBD included_VBN as_IN "_`` patients_NNS "_'' in_IN this_DT analysis_NN ._SENT Control_NN samples_NNS were_VBD selected_VBN from_IN clinics_NNS performing_VBG well-child_JJ care_NN or_CC allergy_NN evaluations_NNS (_( children_NNS with_IN negative_JJ RAST_NN tests_NNS )_) ._SENT Institutional_JJ review_NN board_NN approval_NN was_VBD obtained_VBN for_IN this_DT study_NN ,_, and_CC consent_NN was_VBD obtained_VBN from_IN each_DT participating_VBG patient_NN or_CC parent_NN of_IN the_DT patient_NN ._SENT Three-color_NP flow_NN cytometry_NN was_VBD performed_VBN to_TO define_VB CD3_NP ,_, CD4_NP ,_, and_CC CD25_NP ._SENT Only_RB CD25hi_NP CD4_NP T_NN cells_NNS were_VBD included_VBN in_IN the_DT CD25-positive_JJ gate_NN ,_, in_IN accordance_NN with_IN what_WP is_VBZ known_VBN regarding_VBG the_DT expression_NN of_IN CD25_NP on_IN human_JJ regulatory_JJ T_NN cells_NNS ._SENT The_DT fraction_NN of_IN CD25_NP T_NN cells_NNS within_IN the_DT CD3_NP population_NN and_CC the_DT frequency_NN of_IN CD25_NP T_NN cells_NNS within_IN the_DT CD4_NP population_NN did_VBD not_RB vary_VB with_IN age_NN and_CC showed_VBD no_DT difference_NN between_IN controls_NNS and_CC patients_NNS ._SENT In_IN both_DT patients_NNS and_CC controls_NNS ,_, the_DT CD25_NP fraction_NN of_IN CD4_NP T_NN cells_NNS was_VBD typically_RB 6_CD to_TO 15_CD %_NN ._SENT In_IN both_DT patients_NNS and_CC controls_NNS ,_, the_DT CD25_NP fraction_NN of_IN CD3_NP T_NN cells_NNS was_VBD typically_RB 2_CD to_TO 10_CD %_NN ._SENT Differences_NNS were_VBD readily_RB apparent_JJ between_IN patients_NNS and_CC controls_NNS when_WRB the_DT CD4_NP CD25_NP proportion_NN of_IN total_JJ lymphocytes_NNS was_VBD examined_VBN and_CC the_DT CD4_NP CD25_NP absolute_JJ number_NN was_VBD determined_VBN ._SENT There_EX is_VBZ a_DT distinct_JJ age-related_JJ decline_NN in_IN the_DT CD4_NP CD25_NP fraction_NN and_CC number_NN of_IN cells_NNS from_IN birth_NN through_IN approximately_RB 36_CD months_NNS of_IN age_NN in_IN the_DT controls_NNS ._SENT The_DT differences_NNS between_IN the_DT CD4_NP CD25_NP T-cell_NN numbers_NNS in_IN children_NNS less_JJR than_IN 3_CD years_NNS of_IN age_NN and_CC those_DT over_IN 9_CD years_NNS of_IN age_NN are_VBP significant_JJ ,_, with_IN P_NN being_VBG 0.001_CD ._SENT In_IN contrast_NN ,_, the_DT fraction_NN and_CC number_NN of_IN CD4_NP CD25_NP T_NN cells_NNS were_VBD similar_JJ throughout_IN all_DT ages_NNS examined_VBN in_IN the_DT chromosome_NN 22q11.2_JJ deletion_NN population_NN ._SENT As_IN a_DT result_NN ,_, the_DT fraction_NN and_CC the_DT absolute_JJ number_NN are_VBP markedly_RB lower_JJR in_IN the_DT patients_NNS than_IN controls_NNS in_IN infancy_NN ._SENT The_DT mean_JJ CD4_NP CD25_NP T-cell_NN count_NN in_IN patients_NNS under_IN 3_CD years_NNS of_IN age_NN was_VBD 7_CD cells/mm3_NN ,_, while_IN it_PP was_VBD 75_CD cells/mm3_NN in_IN the_DT controls_NNS (_( P_NN =_SYM 0.001_CD )_) ._SENT The_DT mean_JJ CD4_NP CD25_NP T-cell_NN count_NN in_IN patients_NNS 3_CD to_TO 9_CD years_NNS of_IN age_NN was_VBD 3_CD cells/mm3_NN ,_, while_IN it_PP was_VBD 14_CD cells/mm3_NN in_IN controls_NNS (_( P_NN =_SYM 0.005_CD )_) ._SENT The_DT mean_JJ CD4_NP CD25_NP T-cell_NN count_NN in_IN patients_NNS over_IN the_DT age_NN of_IN 9_CD years_NNS was_VBD 3_CD cells/mm3_NN ,_, while_IN it_PP was_VBD 10_CD cells/mm3_NN in_IN controls_NNS (_( P_NN =_SYM 0.002_CD )_) ._SENT Six_CD patients_NNS had_VBD autoimmune_JJ disease_NN ._SENT The_DT mean_JJ CD4_NP CD25_NP T-cell_NN count_NN in_IN these_DT six_CD patients_NNS was_VBD no_RB different_JJ than_IN the_DT mean_NN in_IN the_DT non-autoimmune_JJ disease_NN patients_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM (_( Top_JJ )_) Fractions_NNS of_IN CD4_NP CD25_NP T_NN cells_NNS within_IN the_DT total_JJ lymphocyte_NN gate_NN ;_: (_( bottom_JJ )_) absolute_JJ numbers_NNS of_IN CD4_NP CD25_NP T_NN cells_NNS ._SENT (_( Top_JJ )_) Fractions_NNS of_IN CD4_NP CD25_NP T_NN cells_NNS within_IN the_DT total_JJ lymphocyte_NN gate_NN ;_: (_( bottom_JJ )_) absolute_JJ numbers_NNS of_IN CD4_NP CD25_NP T_NN cells_NNS ._SENT Gray_JJ diamonds_NNS represent_VBP patients_NNS with_IN autoimmune_JJ disease_NN ._SENT m_NN ,_, months_NNS ._SENT This_DT is_VBZ the_DT first_JJ study_NN to_TO examine_VB peripheral_JJ blood_NN CD4_NP CD25_NP T_NN cells_NNS in_IN human_JJ children_NNS ._SENT We_PP have_VBP shown_VBN that_IN newborns_NNS generally_RB have_VBP high_JJ numbers_NNS that_WDT decline_VBP rapidly_RB over_IN the_DT first_JJ 2_CD to_TO 3_CD years_NNS of_IN life_NN ._SENT This_DT is_VBZ dependent_JJ on_IN T-cell_NN production_NN ,_, because_IN the_DT fraction_NN of_IN CD4_NP CD25_NP cells_NNS within_IN the_DT T-cell_NN subset_NN remains_VBZ relatively_RB constant_JJ throughout_IN childhood_NN ._SENT Patients_NNS with_IN chromosome_NN 22q11.2_JJ deletion_NN with_IN developmental_JJ thymic_JJ hypoplasia_NN have_VBP markedly_RB fewer_JJR CD4_NP CD25_NP T_NN cells_NNS in_IN infancy_NN ._SENT The_DT significance_NN of_IN these_DT findings_NNS is_VBZ twofold_JJ ._SENT Patients_NNS with_IN chromosome_NN 22q11.2_JJ deletion_NN syndrome_NN have_VBP a_DT relatively_RB pure_JJ quantitative_JJ defect_NN in_IN T-cell_NN production_NN ._SENT Thus_RB ,_, this_DT study_NN suggests_VBZ that_DT regulation_NN of_IN CD4_NP CD25_NP T-cell_NN production_NN early_RB in_IN life_NN in_IN humans_NNS is_VBZ directly_RB related_VBN to_TO thymic_JJ capacity_NN ._SENT CD4_NP CD25_NP T_NN cells_NNS are_VBP produced_VBN in_IN similar_JJ proportions_NNS with_IN other_JJ T_NN cells_NNS postnatally_RB ._SENT Secondly_RB ,_, this_DT study_NN suggests_VBZ that_IN one_CD contributor_NN to_TO the_DT increased_VBN prevalence_NN of_IN autoimmune_JJ disease_NN could_MD be_VB diminished_VBN CD4_NP CD25_NP T_NN cells_NNS ._SENT This_DT is_VBZ comparable_JJ to_TO what_WP was_VBD seen_VBN in_IN the_DT murine_JJ neonatal_JJ thymectomy_NN model_NN ._SENT The_DT CD4_NP CD25_NP T_NN cells_NNS appear_VBP late_JJ ,_, and_CC the_DT absolute_JJ numbers_NNS remain_VBP diminished_VBN ._SENT In_IN this_DT murine_JJ model_NN ,_, approximately_RB 20_CD %_NN of_IN the_DT mice_NNS developed_VBD autoimmune_JJ gastritis_NN by_IN 1.5_CD to_TO 3_CD months_NNS of_IN age_NN after_IN neonatal_JJ thymectomy_NN ._SENT Extrapolating_VBG from_IN the_DT murine_JJ model_NN ,_, our_PP$ finding_NN of_IN markedly_RB diminished_VBN CD4_NP CD25_NP T-cell_NN numbers_NNS early_JJ in_IN life_NN suggests_VBZ that_IN this_DT phenomenon_NN could_MD play_VB a_DT role_NN in_IN the_DT predisposition_NN to_TO autoimmune_JJ disease_NN in_IN patients_NNS with_IN chromosome_NN 22q11.2_JJ deletion_NN syndrome_NN ._SENT Other_JJ factors_NNS are_VBP required_VBN to_TO define_VB the_DT type_NN of_IN autoimmune_JJ disease_NN and_CC to_TO further_RBR determine_VB susceptibility_NN ._SENT 